flecainide has been researched along with Asystole in 24 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Cardiac Arrhythmia Suppression Trial (CAST) was a multicenter double-blind, placebo-controlled study designed to determine whether suppression of ventricular ectopic activity by means of antiarrhythmic drugs (encainide, flecainide or moricizine) after acute myocardial infarction would reduce the incidence of arrhythmic death." | 9.07 | Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST). ( Barker, AH; Brooks, MM; Capone, R; Echt, DS; Greene, HL; Liebson, PR; Mitchell, LB; Peters, RW, 1994) |
| "This report examines whether in the Cardiac Arrhythmia Suppression Trial death and cardiac arrest from encainide, flecainide and moricizine during the titration phase and from encainide and flecainide during the follow-up phase were related to presence (Q-wave acute myocardial infarction [Q-AMI]) or absence (non-Q-AMI) of pathologic Q waves." | 9.07 | Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. ( Akiyama, T; Greenberg, H; Kuo, CS; Pawitan, Y; Reynolds-Haertle, RA, 1991) |
| "In the Cardiac Arrhythmia Suppression Trial, designed to test the hypothesis that suppression of ventricular ectopy after a myocardial infarction reduces the incidence of sudden death, patients in whom ventricular ectopy could be suppressed with encainide, flecainide, or moricizine were randomly assigned to receive either active drug or placebo." | 9.07 | Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. ( Arensberg, D; Baker, A; Barker, AH; Echt, DS; Friedman, L; Greene, HL; Liebson, PR; Mitchell, LB; Obias-Manno, D; Peters, RW, 1991) |
| "The efficacy and safety of flecainide were studied in the maintenance of sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter." | 9.06 | Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. ( Crijns, HJ; Hamer, HP; Lie, KI; Van Gelder, IC; Van Gilst, WH; Van Wijk, LM, 1989) |
| "In patients with false-negative responses to the provocative testing with flecainide, cardiac syncope predicts SCA, allowing a more extensive and individualized evaluation." | 7.88 | Role of syncope in predicting adverse outcomes in patients with suspected Brugada syndrome undergoing standardized flecainide testing. ( Avanzas, P; Calvo, D; Coto, E; García, D; Gómez, J; González-Vasserot, M; María de la Hera, J; Morís, C; Pablo Flórez, J; Pérez, D; Reguero, J; Rubín, J; Valverde, I, 2018) |
| "The Cardiac Arrhythmia Suppression Trial (CAST) was a multicenter double-blind, placebo-controlled study designed to determine whether suppression of ventricular ectopic activity by means of antiarrhythmic drugs (encainide, flecainide or moricizine) after acute myocardial infarction would reduce the incidence of arrhythmic death." | 5.07 | Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST). ( Barker, AH; Brooks, MM; Capone, R; Echt, DS; Greene, HL; Liebson, PR; Mitchell, LB; Peters, RW, 1994) |
| "This report examines whether in the Cardiac Arrhythmia Suppression Trial death and cardiac arrest from encainide, flecainide and moricizine during the titration phase and from encainide and flecainide during the follow-up phase were related to presence (Q-wave acute myocardial infarction [Q-AMI]) or absence (non-Q-AMI) of pathologic Q waves." | 5.07 | Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. ( Akiyama, T; Greenberg, H; Kuo, CS; Pawitan, Y; Reynolds-Haertle, RA, 1991) |
| "In the Cardiac Arrhythmia Suppression Trial, designed to test the hypothesis that suppression of ventricular ectopy after a myocardial infarction reduces the incidence of sudden death, patients in whom ventricular ectopy could be suppressed with encainide, flecainide, or moricizine were randomly assigned to receive either active drug or placebo." | 5.07 | Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. ( Arensberg, D; Baker, A; Barker, AH; Echt, DS; Friedman, L; Greene, HL; Liebson, PR; Mitchell, LB; Obias-Manno, D; Peters, RW, 1991) |
| "The efficacy and safety of flecainide were studied in the maintenance of sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter." | 5.06 | Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. ( Crijns, HJ; Hamer, HP; Lie, KI; Van Gelder, IC; Van Gilst, WH; Van Wijk, LM, 1989) |
| "In patients with false-negative responses to the provocative testing with flecainide, cardiac syncope predicts SCA, allowing a more extensive and individualized evaluation." | 3.88 | Role of syncope in predicting adverse outcomes in patients with suspected Brugada syndrome undergoing standardized flecainide testing. ( Avanzas, P; Calvo, D; Coto, E; García, D; Gómez, J; González-Vasserot, M; María de la Hera, J; Morís, C; Pablo Flórez, J; Pérez, D; Reguero, J; Rubín, J; Valverde, I, 2018) |
| "Flecainide is recommended as a first-line antiarrhythmic drug to maintain normal sinus rhythm in patients with atrial fibrillation (AF) who have structurally normal hearts or hypertension without left ventricular hypertrophy." | 3.80 | An unusual case of flecainide-induced QT prolongation leading to cardiac arrest. ( Costa, SM; Mixon, TA; Oguayo, KN; Oyetayo, OO, 2014) |
| "After suicidal ingestion of 3 g flecainide a 34-year-old woman showed somnolence, cerebral convulsion, disturbances of atrioventricular and intraventricular conduction and ventricular asystole." | 3.68 | [Successful treatment of flecainide (Tambocor) poisoning--effect of hemodialysis/hemoperfusion?]. ( Dirks, E; Gieshoff, B; Hager, W; Stahlmann, R; Wehr, M, 1990) |
| "This multicenter study suggests that oral flecainide therapy is an effective and safe means of suppressing VAs in patients with ATS with KCNJ2 mutations, though the U-wave amplitude remained unchanged by flecainide." | 2.80 | Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations. ( Aiba, T; Anzai, T; Hayashi, H; Horie, M; Ishibashi, K; Ishihara, M; Kamakura, S; Kimura, H; Kusano, K; Miyamoto, K; Miyamoto, Y; Nakajima, I; Noda, T; Ogawa, H; Ohno, S; Okamura, H; Shimizu, W; Tanioka, Y; Tsuboi, I; Tsuchiya, T; Yasuda, S; Yasuoka, C; Yoshida, Y, 2015) |
| "The short QT syndrome is characterized by familial sudden death, short refractory periods, and inducible ventricular fibrillation." | 2.71 | Short QT Syndrome: a familial cause of sudden death. ( Bianchi, F; Borggrefe, M; Gaita, F; Giustetto, C; Grossi, S; Riccardi, R; Richiardi, E; Schimpf, R; Wolpert, C, 2003) |
| "There were 63 deaths/resuscitated cardiac arrests in the active treatment (encainide/flecainide) group and 26 in the placebo group." | 2.67 | Prevalence, characteristics and significance of ventricular premature complexes and ventricular tachycardia detected by 24-hour continuous electrocardiographic recording in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. ( Denes, P; Gillis, AM; Kammerling, JM; Pawitan, Y; Salerno, DM; Wilhelmsen, L, 1991) |
| "Patients with unexplained ventricular arrhythmias (UVA) were identified as those with no structural heart disease on echocardiogram, no obstructive coronary disease, and no clear diagnostic features on ECG." | 1.91 | Diagnostic evaluation of unexplained ventricular tachyarrhythmias in younger adults. ( Kistler, P; Ling, LH; Mariani, J; Patel, H; Prabhu, S; Shirwaiker, A; Sugamar, H; Voskoboinik, A; William, J; Xiao, X, 2023) |
| "Flecainide is a Class Ic antiarrythmic agent associated with adverse events due to its pro-arrythmic effects." | 1.42 | Life-threatening flecainide overdose treated with intralipid and extracorporeal membrane oxygenation. ( Bernard, KR; Brumfield, E; Kabrhel, C, 2015) |
| "Unexplained cardiac arrest (UCA) can be caused by low-penetrance genetic disorders." | 1.42 | Diagnostic Approach to Unexplained Cardiac Arrest (from the FIVI-Gen Study). ( Álvarez, M; Cózar, R; Domingo, D; Fernández Pastor, J; Gimeno, JR; Grima, EZ; Heras, RP; Jiménez-Jáimez, J; Mazuelos, F; Monserrat, L; Moriña, P; Ortiz-Genga, M; Peinado, R; Sánchez Muñoz, JJ; Segura, F; Tercedor, L, 2015) |
| "Flecainide is a class Ic antidysrhythmic agent used to prevent and treat tachydysrhythmias." | 1.42 | Successful treatment of flecainide-induced cardiac arrest with extracorporeal membrane oxygenation in the ED. ( Judge, BS; Reynolds, JC, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (16.67) | 18.7374 |
| 1990's | 8 (33.33) | 18.2507 |
| 2000's | 3 (12.50) | 29.6817 |
| 2010's | 8 (33.33) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| William, J | 1 |
| Xiao, X | 1 |
| Shirwaiker, A | 1 |
| Patel, H | 1 |
| Prabhu, S | 1 |
| Ling, LH | 1 |
| Sugamar, H | 1 |
| Mariani, J | 1 |
| Kistler, P | 1 |
| Voskoboinik, A | 1 |
| Poli, S | 1 |
| Toniolo, M | 1 |
| Maiani, M | 1 |
| Zanuttini, D | 1 |
| Rebellato, L | 1 |
| Vendramin, I | 1 |
| Dametto, E | 1 |
| Bernardi, G | 1 |
| Bassi, F | 1 |
| Napolitano, C | 1 |
| Livi, U | 1 |
| Proclemer, A | 1 |
| Pablo Flórez, J | 1 |
| García, D | 1 |
| Valverde, I | 1 |
| Rubín, J | 1 |
| Pérez, D | 1 |
| González-Vasserot, M | 1 |
| Reguero, J | 1 |
| María de la Hera, J | 1 |
| Avanzas, P | 1 |
| Gómez, J | 1 |
| Coto, E | 1 |
| Morís, C | 1 |
| Calvo, D | 1 |
| Oguayo, KN | 1 |
| Oyetayo, OO | 1 |
| Costa, SM | 1 |
| Mixon, TA | 1 |
| Miyamoto, K | 1 |
| Aiba, T | 1 |
| Kimura, H | 1 |
| Hayashi, H | 2 |
| Ohno, S | 1 |
| Yasuoka, C | 1 |
| Tanioka, Y | 1 |
| Tsuchiya, T | 1 |
| Yoshida, Y | 1 |
| Tsuboi, I | 1 |
| Nakajima, I | 1 |
| Ishibashi, K | 1 |
| Okamura, H | 1 |
| Noda, T | 1 |
| Ishihara, M | 1 |
| Anzai, T | 1 |
| Yasuda, S | 1 |
| Miyamoto, Y | 1 |
| Kamakura, S | 1 |
| Kusano, K | 1 |
| Ogawa, H | 1 |
| Horie, M | 1 |
| Shimizu, W | 1 |
| Brumfield, E | 1 |
| Bernard, KR | 1 |
| Kabrhel, C | 1 |
| Jiménez-Jáimez, J | 1 |
| Peinado, R | 1 |
| Grima, EZ | 1 |
| Segura, F | 1 |
| Moriña, P | 1 |
| Sánchez Muñoz, JJ | 1 |
| Mazuelos, F | 1 |
| Cózar, R | 1 |
| Gimeno, JR | 1 |
| Heras, RP | 1 |
| Monserrat, L | 1 |
| Domingo, D | 1 |
| Ortiz-Genga, M | 1 |
| Fernández Pastor, J | 1 |
| Álvarez, M | 1 |
| Tercedor, L | 1 |
| Reynolds, JC | 1 |
| Judge, BS | 1 |
| Behr, ER | 1 |
| Camm, AJ | 2 |
| Kiblboeck, D | 1 |
| Braeuer-Mocker, M | 1 |
| Siostrzonek, P | 1 |
| Reisinger, J | 1 |
| Gaita, F | 1 |
| Giustetto, C | 1 |
| Bianchi, F | 1 |
| Wolpert, C | 1 |
| Schimpf, R | 1 |
| Riccardi, R | 1 |
| Grossi, S | 1 |
| Richiardi, E | 1 |
| Borggrefe, M | 1 |
| Junttila, MJ | 1 |
| Gonzalez, M | 1 |
| Lizotte, E | 1 |
| Benito, B | 1 |
| Vernooy, K | 1 |
| Sarkozy, A | 1 |
| Huikuri, HV | 1 |
| Brugada, P | 1 |
| Brugada, J | 1 |
| Brugada, R | 1 |
| Peters, RW | 2 |
| Mitchell, LB | 2 |
| Brooks, MM | 1 |
| Echt, DS | 2 |
| Barker, AH | 2 |
| Capone, R | 1 |
| Liebson, PR | 2 |
| Greene, HL | 2 |
| Buss, J | 1 |
| Lasserre, JJ | 1 |
| Heene, DL | 1 |
| Denes, P | 1 |
| Gillis, AM | 1 |
| Pawitan, Y | 2 |
| Kammerling, JM | 1 |
| Wilhelmsen, L | 1 |
| Salerno, DM | 1 |
| Akiyama, T | 1 |
| Greenberg, H | 1 |
| Kuo, CS | 1 |
| Reynolds-Haertle, RA | 1 |
| Palitzsch, KD | 1 |
| Bode, H | 1 |
| Huck, K | 1 |
| Usadel, KH | 1 |
| Obias-Manno, D | 1 |
| Arensberg, D | 1 |
| Baker, A | 1 |
| Friedman, L | 1 |
| Fish, FA | 1 |
| Gillette, PC | 1 |
| Benson, DW | 1 |
| Dirks, E | 1 |
| Gieshoff, B | 1 |
| Stahlmann, R | 1 |
| Wehr, M | 1 |
| Hager, W | 1 |
| Van Gelder, IC | 1 |
| Crijns, HJ | 1 |
| Van Gilst, WH | 1 |
| Van Wijk, LM | 1 |
| Hamer, HP | 1 |
| Lie, KI | 1 |
| Woodburn, JD | 1 |
| Ward, D | 1 |
| Garratt, C | 1 |
| Satta, S | 1 |
| Rogers, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000526] | Phase 3 | 0 participants | Interventional | 1986-08-31 | Completed | ||
| Acute Mechanical Response to Anti-arrhythmic Drug Therapy[NCT02575534] | 0 participants (Actual) | Interventional | 2015-10-31 | Withdrawn (stopped due to No enrollment in study.) | |||
| Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL[NCT01576042] | 27 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to Main objectives of the study were met; consensus among investigators that continuing the study would not add new information beyond that already learned.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Records participants hospitalized for VT during the study (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 7 |
Records participants who completed Month 3 Follow-Up Visit (NCT01576042)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 12 |
Records participants who completed Month 6 Follow-Up Visit (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 7 |
| Antiarrhythmic Medication | 10 |
Records participants who had at least one of the efficacy outcome measurement (including death, hospitalization due to VT) (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who received study randomized treatment during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who only received study treatment as randomized during the entire study (NCT01576042)
Timeframe: 6 month
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 6 |
| Antiarrhythmic Medication | 13 |
Records participants who received study treatment as randomized and later switched to other treatment arm during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 1 |
Days from the date of the first study treatment to the date of first ICD recurrent therapy for VT. (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | Days (Mean) |
|---|---|
| Catheter Ablation | 70.1 |
| Antiarrhythmic Medication | 78.7 |
2 reviews available for flecainide and Asystole
| Article | Year |
|---|---|
Management of untreatable ventricular arrhythmias during pharmacologic challenges with sodium channel blockers for suspected Brugada syndrome.
Topics: Action Potentials; Adolescent; Adult; Aged; Aged, 80 and over; Ajmaline; Brugada Syndrome; Cardiopul | 2018 |
Induced Brugada-type electrocardiogram, a sign for imminent malignant arrhythmias.
Topics: Adult; Age of Onset; Anesthetics; Antidepressive Agents, Tricyclic; Brugada Syndrome; Cocaine; Death | 2008 |
7 trials available for flecainide and Asystole
| Article | Year |
|---|---|
Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations.
Topics: Administration, Oral; Adolescent; Adult; Andersen Syndrome; Anti-Arrhythmia Agents; Electrocardiogra | 2015 |
Short QT Syndrome: a familial cause of sudden death.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Premature; Ch | 2003 |
Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST).
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aspirin; Circadian Rhythm; Death, Sudden, Cardia | 1994 |
Prevalence, characteristics and significance of ventricular premature complexes and ventricular tachycardia detected by 24-hour continuous electrocardiographic recording in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.
Topics: Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Cross-Sectional Studies; Electric Countershock | 1991 |
Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.
Topics: Cardiac Complexes, Premature; Cause of Death; Drug Combinations; Electrocardiography; Encainide; Fem | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutte | 1989 |
15 other studies available for flecainide and Asystole
| Article | Year |
|---|---|
Diagnostic evaluation of unexplained ventricular tachyarrhythmias in younger adults.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Flecainide; Heart Arrest; Humans; Retro | 2023 |
Role of syncope in predicting adverse outcomes in patients with suspected Brugada syndrome undergoing standardized flecainide testing.
Topics: Adult; Anti-Arrhythmia Agents; Brugada Syndrome; Electrocardiography; False Negative Reactions; Fema | 2018 |
An unusual case of flecainide-induced QT prolongation leading to cardiac arrest.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Defibrillators; Flecainide; Heart Arrest; Humans | 2014 |
Life-threatening flecainide overdose treated with intralipid and extracorporeal membrane oxygenation.
Topics: Adult; Anti-Arrhythmia Agents; Drug Overdose; Electrocardiography; Extracorporeal Membrane Oxygenati | 2015 |
Diagnostic Approach to Unexplained Cardiac Arrest (from the FIVI-Gen Study).
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Catheteri | 2015 |
Successful treatment of flecainide-induced cardiac arrest with extracorporeal membrane oxygenation in the ED.
Topics: Anti-Arrhythmia Agents; Emergency Service, Hospital; Extracorporeal Membrane Oxygenation; Female; Fl | 2015 |
Letter by Behr and Camm regarding article, "Induced Brugada-type electrocardiogram, a sign for imminent malignant arrhythmias".
Topics: Adult; Age of Onset; Anesthetics; Antidepressive Agents, Tricyclic; Brugada Syndrome; Cocaine; Death | 2008 |
A misguided 'pill in the pocket' approach with flecainide leading to cardiac arrest.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Block; Cardiopulmonary Resuscita | 2012 |
Asystole and cardiogenic shock due to combined treatment with verapamil and flecainide.
Topics: Aged; Drug Therapy, Combination; Flecainide; Heart Arrest; Humans; Male; Shock, Cardiogenic; Verapam | 1992 |
[Successful multiple resuscitation in flecainide poisoning].
Topics: Adult; Electric Countershock; Electrocardiography; Female; Flecainide; Follow-Up Studies; Heart Arre | 1992 |
Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Death, Sudden; Encainide; Flecainide; | 1991 |
[Successful treatment of flecainide (Tambocor) poisoning--effect of hemodialysis/hemoperfusion?].
Topics: Adult; Drug Overdose; Electrocardiography; Female; Flecainide; Heart Arrest; Hemoperfusion; Humans; | 1990 |
Cardiac arrest from a daily newspaper article.
Topics: Aged; Flecainide; Heart Arrest; Humans; Male; Newspapers as Topic; Publishing; Substance Withdrawal | 1989 |
Cardiac arrhythmia suppression trial and flecainide.
Topics: Flecainide; Heart Arrest; Humans; Myocardial Infarction; Product Surveillance, Postmarketing; Tachyc | 1989 |
Flecainide overdose.
Topics: Adult; Female; Flecainide; Heart Arrest; Humans | 1987 |